China Pharma Announces the Entry of "At-The-Market" Equity Offering
HAIKOU, China, Dec. 13, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," or the "Company"), a specialty pharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities...
Kuaishou Technology Wins Award of Excellence in ESG
HONG KONG, Dec. 13, 2024 /PRNewswire/ -- Kuaishou Technology ("Kuaishou" or the "Company"; HKD Counter Stock Code: 01024 / RMB Counter Stock Code: 81024), a leading content community and social platform, is pleased to announce that the Company...
51Talk Online Education Group Announces Third Quarter 2024 Results
SINGAPORE, Dec. 13, 2024 /PRNewswire/ -- 51Talk Online Education Group ("51Talk" or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, today announced its unaudited results for the third...
MGSD Announces Results for 2024 Fiscal Year
NEW YORK, Dec. 13, 2024 /PRNewswire/ -- Maitong Sunshine Cultural Development Co., Ltd (OTCQB: MGSD), an enterprise that provides cultural tourism services and other related services and products, announced its financial results for the year ended...
Accropeutics Inc. Announces U.S. FDA Clearance of IND Application for RIPK2 Inhibitor AC-101
Company to conduct a Phase II multi-regional clinical trial (MRCT) for the treatment of Ulcerative Colitis (UC) A Phase Ib Study of AC-101 for Ulcerative Colitis (UC) has been initiated in China AC-101 demonstrated a favorable safety and PK/PD...
Lichen China Limited Announces $2.70 Million Registered Direct Offering
XIAMEN, China, Dec. 13, 2024 /PRNewswire/ -- Lichen China Limited (Nasdaq: LICN) ("Lichen China" or the "Company"), a dedicated financial and taxation service provider in China today announced that it has entered into a definitive agreement with...
MMTEC, Inc. Announces 1-for-8 Reverse Stock Split
HONG KONG, Dec. 12, 2024 /PRNewswire/ -- MMTEC, Inc. ("MMTEC" or the "Company") (Nasdaq: MTC) reported that it expects to implement a 1-for-8 reverse stock split on its common stock. The effective date is scheduled to be December 18, 2024, subject...
CureGene Received Clinical Trial Approval in China for CG-0255 for Injection - A Novel Antiplatelet Therapy
SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- CureGene Pharmaceutical ("CureGene"), a biotechnology company dedicated to innovative treatments for critical unmet medical needs in cardio-cerebrovascular and antiviral disease, proudly announces the approval...
Altair Announces Partnership with CGI to Drive IT Modernization and AI Innovation
TROY, Mich., Dec. 12, 2024 /PRNewswire/ -- Altair (Nasdaq: ALTR), a global leader in computational intelligence, has announced a partnership with CGI, one of the largest independent IT and business consulting services firms in the world. The...
KIND Presents Preclinical Results of AND017 in Animal Models of Sickle Cell Disease (SCD), Myelodysplastic Syndromes (MDS), and β-Thalassemia at the 66th American Society of Hematology Meeting and Exposition and Announces FDA Authorization of Investigatio
SAN FRANCISCO, Dec. 12, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological...